• Study reports abnormally high VTE and high bleed risk in critically ill COVID-19 patients and calls for more effective prevention strategies.
  • Clinicians at NHS hospitals are supporting the care of COVID-19 patients with the use of geko™ devices to reduce the risk of blood clots in the most at risk patients.
Learn more Contact us

Wound therapy

Welsh Wound Innovation Centre
& The University of Cardiff,
School of Medicine

Breaking the cycle of chronic wounds

Read Less

At the Welsh Wound Innovation Centre (WWIC) we are devoted to embracing new models of care to tackle the silent epidemic of wounds. In collaboration with Firstkind we have evaluated the therapeutic effect of the geko™ device on wound healing outcomes over an 8 week period.

Through a case series evaluation we have generated evidence that fills us with interest and excitement. All patients treated gained benefit from the geko™ device. Many saw a reduction in ulcer size after only a short period of therapy. Perhaps the most important observation was the notable improvement in patient quality of life and a reduction of pain1. We had not been expecting to see such a dramatic improvement using the geko™ device.

The results support use of geko™ in patients with hard-to-heal, painful venous and mixed leg ulceration, in conjunction with best practice standard care1.

Results show1:

  • Reduction in wound surface area.
  • An increased in granulation tissue formation.
  • 7% of patients with wounds of venous aetiology (VLU) achieved complete re-epithelialisation over the 8-week evaluation period.
  • 52% reported a substantial reduction in wound pain.
  • All patients reported a 100% satisfaction with the gekoTM
  • Patients reported the geko™ as easy to operate with minimal disruption to daily living.
  • Patients were enabled to self-manage the device and take control over their symptoms whilst resuming their normal daily activities.

Contrast speckle imaging data from a single WWIC case study (shown above) demonstrates a 225% increase in microcirculatory blood flow in the wound bed, and a 67% increase in microcirculatory blood flow surrounding the peri-wound area, after activation of the geko™ device. The increase in blood flow to the wound bed promotes conditions favourable to wound healing2.


At baseline visit

Patient with venous leg ulcer (VLU).

Final visit at 8 weeks

Complete re-epitheliailisation achieved in conjunction with compression therapy.


225% increase in microcirculatory blood flow in the wound bed (p>0.001)


  1. N.J. Jones & Prof. Keith Harding et al. Abstract: A case series evaluating the geko™ neuromuscular electrostimulation device on lower limb wounds of differing aetiology.
  2. Warwick D, et al. Microcirculation in the foot is augmented by neuromuscular stimulation via the common peroneal nerve in different lower limb postures: a potential treatment for leg ulcers. International Angiology 2015 April; 34(2):158-65.

OnPulse Technology

The revolutionary neuromuscular electrostimulation technology developed by Firstkind

Find out more

geko™ product

Wound Therapy Applications device

Find out more

Partner with us

What can the geko™ do for my patients?


Al Mahmoud Medical Center, Qatar, adopts the geko™ device for prevention of venous thromboembolism (VTE) and reduction of edema (swelling)


The geko™ device receives UK Conformity Assessed Mark

Social Media

Follow our social media channels to read our latest updates

Social Media